Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- CheckyesterdayChange DetectedRevision version updated to v3.6.6, replacing v3.6.5, indicating a minor site update without altering study data.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 on the site. This represents a minor platform update with no changes to the study details or on-page content.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page version was updated from v3.6.3 to v3.6.4. This appears to be a maintenance update with minor fixes that do not change the study details or user-facing content.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3 on the page, signaling a new version of the site's content or template. This is an internal update and does not alter the study details or user-visible information.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2, signaling a new site/documentation release. This reflects backend/versioning updates rather than changes to study details or user-facing features.SummaryDifference0.0%

- Check80 days agoChange DetectedEnrollment is closed as indicated by the new status. The page adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment labeling and revision version to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.